Licensing opportun Skinvisible operates as an R&D focused company with a clear objective to license patented topical and transdermal products, presenting partnerships as a primary sales avenue for international and multinational pharma, biotech, and consumer goods firms seeking new products or lifecycle management.

Invisicare leverage Leveraging the patented Invisicare technology across diverse dermatology and non-dermatology applications creates cross‑sell opportunities for licensees in areas from obesity and acne to anti-aging and sunscreen products.

Ancillary product line Recent and historical product launches such as Skinbrella sunscreen, Kintari skincare lines, and related pre-surgical preparations indicate a pipeline of consumer and medical products that potential partners may seek to license or co‑develop.

Strategic partnerships Past licensing activity, including exclusive worldwide license agreements (for example with Quoin Pharmaceuticals) and leadership hires, signals a readiness to collaborate with external companies for distribution, marketing, and regional expansion.

Growth potential With revenue in the low millions and a lean employee base, there is an opportunity to scale through license deals, product extensions, and international distribution channels, appealing to larger players seeking incremental growth through dermatology and OTC/OTC-like portfolios.